Find clinical trials for Non-Hodgkin Lymphoma in Aurora, CO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma trials near Aurora, CO, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3


Denver, Colorado, United States and 66 other locations

administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...

Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: CFT7455

Phase 1, Phase 2

C4 Therapeutics

Denver, Colorado, United States and 12 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2


Aurora, Colorado, United States and 37 other locations

patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...

Active, not recruiting
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma
Drug: CG-806

Phase 1

Aptose Biosciences

Aurora, Colorado, United States and 29 other locations

017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment....

Active, not recruiting
Follicular Lymphoma
Mantle-cell Lymphoma
Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule
Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Phase 1

Juno Therapeutics

Aurora, Colorado, United States and 13 other locations

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...

Diffuse Large B Cell Lymphoma (DLBCL)
Biological: bbT369

Phase 1, Phase 2

2seventy bio

Denver, Colorado, United States and 3 other locations

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study desi...

B-cell Non-Hodgkin Lymphomas
Advanced Solid Tumors
Drug: ATG-031

Phase 1


Aurora, Colorado, United States and 3 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Denver, Colorado, United States and 6 other locations

targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)

Denver, Colorado, United States and 9 other locations

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...

Non-Hodgkin Lymphoma
Drug: IV Glofitamab
Drug: CC-99282

Phase 1


Aurora, Colorado, United States and 26 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems